Dr Hornig’s talk in Sweden now available

Dr Mady Hornig, MD, Director of Translational Research at the Center for Infection and Immunity at Columbia University, made a presentation at the RME Sweden Severe ME conference in late October last year.  Dr Hornig went into more depth about her published cytokine work and described what her team is working on today.
Dr Hornig spoke about the crisis in funding, looking at gene expression and gene variants, screening for up to 1.7 million vertebrate viruses, metabolomics, and looking at how the immune system and the microbiome could affect metabolism and the brain.  She also spoke about the need to address the heterogeneity in ME/CFS in terms of symptomology but also illness duration and severity: the presence of sub-groups within the illness, each of which presents its own challenges and may require different treatment strategies.
Here is the full transcript of the talk, together with most of the slides.  Thanks to RME Sweden, it is also available to be viewed on YouTube.
 

Facebook
Twitter
WhatsApp
Email

Latest News

a collection of millionsmisisng pictures featuring people protesting over the years in red shirts and with protest signs. white dashses connect the photos. the words words "the Story of the #MillionsMissing" is in white font in the top lefthand corner with the #MEAction logo there. The words "Coming Soon" is handwriting font is in the top righthand corner.

“#MillionsMissing is our drumbeat”–Preview Party 9/24

RSVP TODAY: We are hosting a preview party for the new, virtual Home of the #MillionsMissing this Sunday, September 24th, at 12 pm PT/ 3 pm ET/ 8 pm BST! RSVP & Get Zoom Link Here We have always had to be creative in telling Our Story – the story of M.E. – to the world

Read More »

JNNP to publish edited rapid response by MEAction UK.

MEAction UK have been in communication with the BMJ and are delighted to announce that the Journal of Neurology, Neurosurgery & Psychiatry (JNNP) are publishing an edited version of our rapid response to  ‘Anomalies in the review process and interpretation of the evidence in the NICE guideline for chronic fatigue syndrome and myalgic encephalomyelitis’. We

Read More »